Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 0.00% is 100% below its 5-year average of 1.36%, near the high end of its 5-year range (-48.53%–6.98%).
As of the fiscal period ended Tuesday, June 30, 2026. 99.83% below its 12-month average of 2.15%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
RETURN ON EQUITY (ROE)
0.00%
RETURN ON EQUITY (ROE) AVG TTM
2.15%
RETURN ON EQUITY (ROE) AVG 3Y
2.73%
RETURN ON EQUITY (ROE) AVG 5Y
1.36%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-99.83%
CURRENT VS 3Y AVG
-99.87%
CURRENT VS 5Y AVG
-99.73%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+100.01%
vs the sector median at left
Privia Health Group, Inc.
Market Cap
$2.57B
Return on Equity (ROE)
0.00%
TTM Avg
2.15%
3Y Avg
2.73%
5Y Avg
1.36%
Market Cap
$2.60B
Return on Equity (ROE)
-8.00%
TTM Avg
-28.91%
3Y Avg
-27.68%
5Y Avg
-39.13%
Market Cap
$2.62B
Return on Equity (ROE)
-0.38%
TTM Avg
-26.55%
3Y Avg
-13.53%
5Y Avg
-6.91%
Market Cap
$2.53B
Return on Equity (ROE)
-41.10%
TTM Avg
-30.86%
3Y Avg
-32.08%
5Y Avg
-34.60%
Market Cap
$2.65B
Return on Equity (ROE)
95.64%
TTM Avg
115.72%
3Y Avg
76.74%
5Y Avg
3213.80%
Market Cap
$2.66B
Return on Equity (ROE)
-25.47%
TTM Avg
-23.80%
3Y Avg
14.67%
5Y Avg
14.67%
Market Cap
$2.67B
Return on Equity (ROE)
-56.91%
TTM Avg
-24.13%
3Y Avg
-9.83%
5Y Avg
-11.19%
Market Cap
$2.46B
Return on Equity (ROE)
-10.66%
TTM Avg
1.75%
3Y Avg
2.62%
5Y Avg
5.68%
Market Cap
$2.73B
Return on Equity (ROE)
-361.91%
TTM Avg
-763.19%
3Y Avg
-396.22%
5Y Avg
-320.76%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Privia Health Group, Inc. (PRVA) | $2.57B | 0.00% | 2.15% | 2.73% | 1.36% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.60B | -8.00% | -28.91% | -27.68% | -39.13% |
| Neogen Corporation (NEOG)vs › | $2.62B | -0.38% | -26.55% | -13.53% | -6.91% |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.53B | -41.10% | -30.86% | -32.08% | -34.60% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.65B | 95.64% | 115.72% | 76.74% | 3213.80% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.66B | -25.47% | -23.80% | 14.67% | 14.67% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.67B | -56.91% | -24.13% | -9.83% | -11.19% |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.46B | -10.66% | 1.75% | 2.62% | 5.68% |
| Precigen, Inc. (PGEN)vs › | $2.73B | -361.91% | -763.19% | -396.22% | -320.76% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.41B | -56.71% | -50.91% | -55.48% | -35.68% |
ROE
0.0%
ROA
0.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 2.89% |
| 2025-12-31 | 3.11% |
| 2025-09-30 | 2.56% |
| 2025-06-30 | 2.17% |
| 2025-03-31 | 2.37% |
| 2024-12-31 | 2.26% |
| 2024-09-30 | 2.09% |
| 2024-06-30 | 2.51% |
| 2024-03-31 | 3.25% |
| 2023-12-31 | 4.11% |
| 2023-09-30 | 6.98% |
| 2023-06-30 | 6.47% |
| 2023-03-31 | 3.17% |
| 2022-12-31 | -1.72% |
| 2022-09-30 | -8.15% |
| 2022-06-30 | -11.03% |
| 2022-03-31 | -48.53% |
| 2021-12-31 | -44.10% |
| 2021-09-30 | -41.98% |
| 2021-06-30 | -37.27% |
| 2021-03-31 | 20.51% |
| 2020-12-31 | 21.29% |
